An interview with Charles A.B. Boucher, MD, PhD. Interview by Mark Mascolini.
Boucher
C A
CA
Academic Hospital, Utrecht, Netherlands.
D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine; D009154:Mutation; D012367:RNA, Viral / Q000097:blood; D016047:Zalcitabine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D015215:Zidovudine / Q000494:pharmacology / Q000627:therapeutic use
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine